Kronik Miyeloid Lösemi için Kullanılan Nilotinib Tedavisi Sonrasında Gelişen Pankreas Kanseri: Bir Olgu Sunumu ve Literatür Derlemesi

Objective & Hypothesis:The patient, a 79-year-old Japanese man, was diagnosed with the chronic phase of chronic myeloid leukemia and begun on nilotinib therapy in April 2011.

📊

Key Findings & Data:About 19 months after the start of nilotinib therapy at 400 mg/day (November 2012), an adenocarcinoma (24x20 mm) confined to the head of the pancreas developed.

💡

Conclusion & Impact:This report describes the case

🔬Design:Research Article

📍Scope:2011 Verileri

⚙️Variables:Domain Parameters

Abstract

The patient, a 79-year-old Japanese man, was diagnosed with the chronic phase of chronic myeloid leukemia and begun on nilotinib therapy in April 2011. The therapeutic response was major molecular response in August. About 19 months after the start of nilotinib therapy at 400 mg/day (November 2012), an adenocarcinoma (24x20 mm) confined to the head of the pancreas developed. In February 2013, a pancreaticoduodenectomy was performed. The therapy regimen was switched to dasatinib at 100 mg/day, beginning in April. The response was still major molecular response with no recurrence of pancreatic carcinoma in July 2013. There have been 29 reported cases of secondary neoplasms associated with nilotinib therapy. These secondary neoplasms were characterized by relatively frequent occurrence of papilloma (6 cases), gastric cancer (3 cases), fibroma (3 cases), and thyroid neoplasms (2 cases). The present case, however, is the first to be reported as carcinoma of the pancreas. This report describes the case

Özet

Yetmiş dokuz yaşında Japon erkek hastaya, Nisan 2011'de kronik evre kronik miyeloid lösemi tanısı konulup, nilotinib tedavisi başlandı. Ağustos'ta majör moleküler yanıt sağlandı. Nilotinib 400 mg/gün dozunda kullanılırken ve tedavi başlangıcından yaklaşık 19 ay geçmişken (Kasım 2012'de), pankreas başına sınırlı (24x20 mm) adenokanser gelişti. Şubat 2013'te pankreatikoduodenektomi yapıldı. Nisan ayından başlayarak tedavi rejimi olarak dasatinib 100 mg/gün'e geçildi. Temmuz 2013'te yanıt halen majör moleküler yanıttı ve pankreas kanserine ait nüks saptanmadı. Literatürde nilotinib tedavisi ile ilişkili olan 29 ikincil neoplazi tespit edildi. Bu ikincil neoplaziler arasında görece daha sık gözlemlenenler papilloma (6 olgu), mide kanseri (3 olgu), fibroma (3 olgu) ve tiroid neoplazileridir (2 olgu). Olgumuz, literatürde nilotinib altında iken gelişen ilk pankreas kanseri olgusudur. Bu yazıda olgu tartışması ve nilotinibe bağlı gelişen ikincil kanserlere ait literatür taraması sunulmaktadır

🔖

Cite This Article

SEKİGUCHİ, Y., SHİMADA, A., MATSUZAWA, M., IMAİ, H., WAKABAYASHİ, M., SUGİMOTO, K., NAKAMURA, N., SAWADA, T., ARİTA, J., KOMATSU, N., NOGUCHİ, M. (2015). Kronik Miyeloid Lösemi için Kullanılan Nilotinib Tedavisi Sonrasında Gelişen Pankreas Kanseri: Bir Olgu Sunumu ve Literatür Derlemesi. Turkish Journal of Hematology, Cilt: 32 - Sayı: 3, 257–262. https://ajindex.com/articles/412821

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (7)

Neoplasm Reference Number Global phase III multicenter trials 9 Gastric cancer: 1 Papilloma of the oral cavity: 1 Thyroid neoplasm: 1 Japanese phase II study 10 Seborrheic keratosis: 1 Overseas phase II study 11 Lipoma: 1 Thyroid neoplasm: 1 Duman et al. Lung cancer: 1 6 Fibroma of the skin: 1 Verma et al. Malignant tumor: 4 4 Postmarketing clinical use surveys in Japan 12 Esophageal cancer: 1 Ureteral cancer: 1 Neoplastic progression: 1 Present case Cancer of the pancreas: 1 Pilot PR, Sablinska K, Owen S, Hatfield A. Epidemiological analysis of second primary malignancies in more than 9500 patients treated with imatinib. Leukemia 2006;20:148-149.
Voglova J, Muzik J, Faber E, Zackova D, Klamova H, Steinerova K, Michalovicova Z, Demitrovicova L, Cmunt E, Novakova L, Tothova E, Belohlavkova P, Mayer J, Indrak K. Incidence of second malignancies during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors in the Czech Republic and Slovakia. Neoplasma 2011;58:256-262.
Roy L, Guilhot J, Martineau G, Larchée R, Guilhot F. Unexpected occurrence of second malignancies in patients treated with interferon followed by imatinib mesylate for chronic myelogenous leukemia. Leukemia 2005;19:1689-1692.
Verma D, Kantarjian H, Strom SS, Rios MB, Jabbour E, Quintas- Cardama A, Verstovsek S, Ravandi F, O'Brien S, Cortes J. Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies. Blood 2011;118:4353-4358.
Gambacorti-Passerini C, Antolini L, Mahon FX, Guilhot F, Deininger M, Fava C, Nagler A, Della Casa CM, Morra E, Abruzzese E, D'Emilio A, Stagno F, le Coutre P, Hurtado- Monroy R, Santini V, Martino B, Pane F, Piccin A, Giraldo P, Assouline S, Durosinmi MA, Leeksma O, Pogliani EM, Puttini M, Jang E, Reiffers J, Valsecchi MG, Kim DW. Multicenter swelling (red arrow). independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst 2011;103:553-561.
Duman BB, Paydas S, Disel U, Besen A, Gurkan E. Secondary malignancy after imatinib therapy: eight cases and review of the literature. Leuk Lymphoma 2012;53:1706-1708. Stein BL. Chronic myeloid leukemia and risk of second malignancy in two eras of treatment. Leuk Lymphoma 2012;53:1651-1653.
Rebora P, Czene K, Antolini L, Gambacorti Passerini C, Reilly M, Valsecchi MG. Are chronic myeloid leukemia patients more at risk for second malignancies? A population-based study. Am J Epidemio